Depuy Synthes Products, Inc.

Janssen Pharmaceutica Nv

Reyna L Favis

Yu Sun

Anthony J Kihm

Haimanti Dorai

Xiang Yao

Stefanie Rassnick

Deborah Ricci

Nadine Cohen

Qingqin S Li

Helgi Van De Velde

The invention relates to methods for detecting allogeneic therapeutic cells (such as human umbilical cord tissue-derived cells (hUTC)) in blood. The methods includes the steps of identifying one or more one or more markers positive for allogeneic therapeutic cells (e.g. hUTC) and one or more markers positive for human peripheral blood mononuclear cells (PBMC); providing a blood sample from a patient that has been treated with allogeneic therapeutic cells (e.g. hUTC), analyzing the sample using an assay method to detect one or more markers positive for PBMC and one or more markers positive for allogeneic therapeutic cells (e.g. hUTC); and distinguishing between the PBMC and one or more markers positive for allogeneic therapeutic cells (e.g. hUTC). In one embodiment, the cells are hUTC and the markers positive of hUTC include CD10 and/or CD13 and the one or more markers positive for PBMC includes CD45.

Detection of human umbilical cord tissue-derived cells

Detection of human umbilical cord tissue derived cells

The present invention provides methods for identifying patients at increased risk of developing an adverse neurological event in response to a cancer treatment. Methods also include modifying the treatment regimen of said patent dependent on the presence or absence of biomarkers in the patient.

Biomarkers for assessing peripheral neuropathy response to cancer treatment

Growing community of inventors

Phillipsburg, NJ, United States of America

Reyna L Favis